Flare Therapeutics has raised a $123M Series B funding round to develop cancer therapies.
Pfizer Ventures was a lead investor.
- The
round was led by GordonMD Global Investments LP and Pfizer Ventures,
with participation from existing investors Boxer Capital, Casdin
Capital, Eventide Asset Management, Invus Financial Advisors, Nextech
Invest, and Third Rock Ventures.
- The company aims to use the funds to support its clinical trial process for FX-909.
- FX-909 is the company's therapy solution that aims to help patients with urothelial cancer.
- The company is based in Boston, Massachusetts.
